Fiduciary Alliance’s CureVac CVAC Stock Holding History

Fiduciary Alliance’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-22	Closed	-$229	–	325
2023 Q2	$229	Buy	+22	New	+$197	﹤0.01%	965
2023 Q1	–	Sell	-22	Closed	-$133	–	301
2022 Q4	$133	Buy	+22	New	+$163	﹤0.01%	916

Other funds holding CVAC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Fiduciary Alliance's CVAC Position: Q3 2023 in Review

Fiduciary Alliance sold out of CureVac (CVAC) in Q3 2023, closing a stake of 22 shares — an estimated $229 sold.

Fiduciary Alliance first reported a position in CVAC in Q4 2022 and held it in 2 quarters. The position peaked at $229 in Q2 2023. 84 funds tracked by Wall St. Rank hold CVAC as of Q3 2023.

Fiduciary Alliance reported no remaining CureVac position as of Q3 2023 after selling out during the quarter.
Fiduciary Alliance sold 22 CureVac shares in Q3 2023, an estimated $229.
Fiduciary Alliance first reported a position in CureVac in Q4 2022 and held it in 2 quarters.
Fiduciary Alliance's CureVac position peaked at $229 in Q2 2023.
84 funds tracked by Wall St. Rank held CureVac as of Q3 2023.

Based on Fiduciary Alliance's 13F filing for Q3 2023, filed 18 Oct 2023.